Journal
FRONTIERS IN IMMUNOLOGY
Volume 6, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2015.00469
Keywords
intravenous immunoglobulin; regulatory T cell; dendritic cell; autoimmunity; immune modulation; cytokine
Categories
Funding
- Talecris
- Grifols Bioscience
- Canadian Institutes for Health Research [CIHR] [ISO115295, MOP67211]
- Research Institute of the McGill University Health Centre (RI-MUHC)
- Fonds de recherche du Quebec - Sante (FRQS)
- Strauss Family Foundation
- CIHR Canada Graduate Scholarships Doctoral Research Award
Ask authors/readers for more resources
Intravenous immunoglobulin (IVIg) is a polyclonal immunoglobulin G preparation with potent immunomodulatory properties. The mode of action of IVIg has been investigated in multiple disease states, with various mechanisms described to account for its benefits. Recent data indicate that IVIg increases both the number and the suppressive capacity of regulatory T cells, a subpopulation of T cells that are essential for immune homeostasis. IVIg alters dendritic cell function, cytokine and chemokine networks, and T lymphocytes, leading to development of regulatory T cells. The ability of IVIg to influence Treg induction has been shown both in animal models and in human diseases. In this review, we discuss data on the potential mechanisms contributing to the interaction between IVIg and the regulatory T-cell compartment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available